ArticleCancers2026

End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy-Modified N7 Regimen with Dinutuximab Beta.

Evelyn R Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.